Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
MARKSANS.NSthis companyMarksans Pharma Limited	₹308.75	17.02×	2.35×	2.41×	11.3×	-65.5%	39.2%	17.1%	14.2%	13.8%	11.1%	4.9%	0.11×	-0.48×	20.92×	5.17×	0.5%	3	—	2	C+
AJANTPHARM.NSAjanta Pharma Limited	₹3,344.00	33.18×	7.74×	6.43×	22.46×	64.5%	51.4%	24.3%	19.4%	23.3%	20.5%	0.4%	0.06×	0.1×	82.23×	2.64×	1.0%	5	18.51	4	A
ALIVUS.NSAlivus Life Sciences Limited	₹1,474.40	21.18×	3.59×	4.69×	14.44×	-46.0%	44.6%	28.3%	22.1%	16.9%	15.6%	2.2%	0.02×	0.07×	134.39×	5.21×	0.5%	—	—	4	A-
APLLTD.NSAlembic Pharmaceuticals Limited	₹1,017.30	19.32×	2.3×	1.77×	12.9×	3.1%	45.1%	10.9%	9.2%	11.9%	10.4%	2.0%	0.25×	1.11×	8.54×	1.76×	1.7%	4	—	2	B-
GLAXO.NSGlaxoSmithKline Pharmaceuticals Limited	₹2,710.00	37.33×	17.06×	10.12×	25.49×	32.4%	43.6%	33.0%	27.1%	45.7%	36.3%	2.5%	0.01×	-0.72×	461.5×	2.03×	1.8%	4	—	2	C+
GRANULES.NSGranules India Limited	₹799.20	25.35×	2.97×	2.81×	13.13×	-42.2%	43.0%	16.6%	11.1%	11.7%	10.1%	0.8%	0.3×	0.52×	7.77×	1.8×	0.2%	5	—	2	C+
Peer median	—	25.35×	3.59×	4.69×	14.44×	3.1%	44.6%	24.3%	19.4%	16.9%	15.6%	2.0%	0.06×	0.1×	82.23×	2.03×	1.0%	5	18.51	2	—